Posted by admin on Nov 30, 2020 in |
Sickle cell anemia is a major life-threatening hemoglobin disorder in the world. This hemoglobin disorder is an autosomal recessive type, therefore considered as a major health problem in the world. The pain symptoms and complications of sickle cell anemia can be life-threatening many times. Management of sickle cell anemia demands drugs to be safe, well-tolerated, lesser side effects, and effective in improving the quality of life in patients. The alternative system of medicine can be the fruitful therapeutic option in conditions where the drug has to be consumed for life long. The T-AYU-HM Premium is a novel traditional Ayurvedic medicine designed on such a purpose to reduce clinical complications and enhance the quality of life in sickle cell anemia patients. The study conducted was a single dose oral toxicity study of T-AYU-HM Premium to assess its safety profile at a high dose. The study was conducted in compliance with the OECD principles of GLP (1998). The study was conducted according to OECD for testing of chemicals, N-425 acute oral...
Read More
Posted by admin on Nov 30, 2020 in |
The inhibition of the protein cyclooxygenase (COX) is a well-known mechanism for achieving analgesia. Selective inhibitors of cyclooxygenase-2 (COX-2) provide excellent analgesia but can have side-effects. In this study, we chose ibuprofen, a non-selective COX inhibitor that has been safely used for a long time, to develop a novel, selective COX-2 inhibitor. The 3-dimensional structure of the drug target, COX-2, was obtained from the RCSB PDB online database and was input in SeeSAR. Three hundred and thirty alterations were made to ibuprofen molecule. Initial docking was performed in SeeSAR and CLC Drug Discovery Workbench to get a docking score. The 216 ligands that bound to COX-2 with the best binding score were then docked to cyclooxygenase-1 protein (COX-1), and a score was generated based on the binding affinity. Twenty-six of these molecules that didn’t bind to COX-1 were chosen as the selective inhibitors of COX-2 and these were tested for drug-likeness properties using the DruLiTo software. Twenty-two compounds with good drug-likeness properties were subjected to ADMET verification. 5 compounds...
Read More
Posted by admin on Nov 30, 2020 in |
Streptozotocin is 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose drug is commonly used to induce diabetes in experimental rats. This study was designed to evaluate the role of β-endorphin and C-peptide in Acu-TENS therapy at Zusanli (ST36) acupoint. Diabetic was induced by Streptozotocin (45mg/kg/body weight) with a single dose of intraperitoneal injection in male albino Wistar rats. The diabetic rats were treated with Acu-TENS electrical stimulation with a pulsed current of low frequency and high intensity at bilateral Zusanli (ST36) acupoint without anesthesia for 60 days, and the effect was compared with pioglitazone (7.5 mg/kg/body weight) treated diabetic rats on fasting blood glucose, β-endorphin & C-peptide levels. The results showed that a significant reduction (p≥0.01) in fasting blood glucose and increased β-endorphin and C-peptide level in Zusanli (ST36) acupoint treated diabetic rats. The anti-diabetic effect of Zusanli (ST36) acupoint may be due to stimulation of Qi (life energy) and regulating the circulation of blood and an increase in insulin secretion through the mediation of β-...
Read More
Posted by admin on Nov 30, 2020 in |
Ropinirole hydrochloride, a non-ergoline dopamine agonist, administered orally for the treatment of Parkinson’s disease and restless leg syndrome and belonged to BCS class III drug having high solubility and low permeability. The objective of the present research study was to enhance the permeability of ropinirole hydrochloride by selecting a suitable permeation enhancing agent from different classes of permeation enhancers. Received pure drug was authenticated by determining its melting point, solubility, stability, apparent partition coefficient and using analytical tools like FTIR, DSC, PXRD and RP-HPLC. The permeation enhancing activity of eight different permeation enhancers was determined in a modified Franz-diffusion cell, the barrier used was rat abdominal skin. The donor compartment consists of an aqueous solution of drug alone, and with a 5% w/v permeation enhancer, and the receptor compartment consists of phosphate-buffered saline pH 7.4. The results of the research study suggested that the received drug was authentic and its purity at par with official pharmacopeia. The ex-vivo permeation kinetic studies showed that all the permeation enhancers are enhancing...
Read More
Posted by admin on Nov 30, 2020 in |
Chikungunya infection, caused by the flavivirus Chikungunya, spreads from one person to another by two species of Aedes mosquitoes, i.e., Aedes albopictus and A. aegypti. There is a rapid global emergence and resurgence of Chikungunya infections in India and the Indian Ocean Islands, making it a public health emergency around the globe. There are numerous strategies being adopted by this arbovirus to evade host immune defences, and as such specific preventive and therapeutic interventions to this fatal and incapacitating disease are still unavailable at large. Hence, under this grave global epidemiological scenario, the development of novel therapeutics against Chikungunya infections in humans is an absolute mandate now. Fortunately, in recent years, experimentations toward new approaches for the prevention and treatment of Chikungunya infections are already underway, with significant success being slowly achieved at the preliminary level of laboratory-based pilot-studies. In this article, we review some of these important advancements achieved in the development of novel chemical therapeutics, immunotherapies, vaccines, and complementary & alternative medicines against Chikungunya virus infections that have shown much promise and...
Read More
